We are live on ! Find out more
SB

Samsara BioCapital Portfolio holdings

AUM $1.03B
1-Year Est. Return 214.94%
This Fund
S&P 500
This Quarter Est. Return
+6.49%
1 Year Est. Return
+214.94%
3 Year Est. Return
+1,814.37%
5 Year Est. Return
+1,842.35%
10 Year Est. Return
–
AUM
$542M
AUM Growth
+$541M
Cap. Flow
+$153M
Cap. Flow %
28.31%
Top 10 Hldgs %
65.43%
Holding
52
New
9
Increased
5
Reduced
6
Closed
8

Top Buys

Rank Stock Value
1
TIL icon
Instil Bio
TIL
+$39.9M
2
BOLT icon
Bolt Biotherapeutics
BOLT
+$24M
3
DBTX
Decibel Therapeutics, Inc. Common Stock
DBTX
+$13M
4
TERN
Terns Pharmaceuticals
TERN
+$10.9M
5
VIRX
Viracta Therapeutics, Inc. Common Stock
VIRX
+$8.66M

Top Sells

Rank Stock Value
1
SWTX
SpringWorks Therapeutics
SWTX
+$7.26M
2
ACRS icon
Aclaris Therapeutics
ACRS
+$6.65M
3
EQ icon
Equillium
EQ
+$2.22M
4
ODT
Odonate Therapeutics, Inc. Common Stock
ODT
+$2.17M
5
BCEL
Atreca, Inc. Class A Common Stock
BCEL
+$1.27M

Sector Composition

Rank Sector Weight
1 Healthcare 89.56%
2 Financials 1.5%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AVDL
26
DELISTED
Avadel Pharmaceuticals
AVDL
$4.96M 0.92%
549,250
+115,000
+26% +$930K
KRON
27
DELISTED
Kronos Bio
KRON
$4.87M 0.9%
166,250
– –
EYPT icon
28
EyePoint Inc
EYPT
$1.2B
$4.57M 0.84%
+450,000
New +$5.06M
RYTM icon
29
Rhythm Pharmaceuticals
RYTM
$7.96B
$4.28M 0.79%
201,046
– –
ALPN
30
DELISTED
Alpine Immune Sciences Inc
ALPN
$4.23M 0.78%
399,190
– –
KALA icon
31
KALA BIO
KALA
$14.5M
$4.05M 0.75%
241
– –
VTGN icon
32
VistaGen Therapeutics
VTGN
$12.8M
$3.9M 0.72%
61,050
+6,371
+12% +$425K
ALBO
33
DELISTED
Albireo Pharma Inc
ALBO
$3.52M 0.65%
100,000
– –
IMCR icon
34
Immunocore
IMCR
$1.73B
$3.41M 0.63%
+80,000
New +$3.56M
BLSA
35
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
$3.17M 0.58%
300,000
– –
CHFW.U
36
DELISTED
Consonance-HFW Acquisition Corp. Units, each consisting of one Class A Ordinary Share, and one-third
CHFW.U
$2.93M 0.54%
300,000
– –
RCKT icon
37
Rocket Pharmaceuticals
RCKT
$394M
$2.83M 0.52%
63,770
– –
ODT
38
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$2.4M 0.44%
700,421
-115,000
-14% -$2.17M
SNCE
39
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
$2.03M 0.37%
10,000
– –
KLRS
40
Kalaris Therapeutics
KLRS
$96.8M
$1.93M 0.36%
3,580
– –
BNTX icon
41
BioNTech
BNTX
$23.5B
$1.18M 0.22%
10,795
– –
NGM
42
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$530K 0.1%
18,225
– –
ATXS
43
DELISTED
Astria Therapeutics
ATXS
$434K 0.08%
25,000
-25,000
-50% -$452K
AMRN
44
Amarin Corp
AMRN
$303M
$155K 0.03%
1,250
– –
COGT icon
45
Cogent Biosciences
COGT
$7.24B
– –
-588,961
Closed -$6.61K
FULC icon
46
Fulcrum Therapeutics
FULC
$297M
– –
-294,118
Closed -$3.44K
GERN icon
47
Geron
GERN
$949M
– –
-1,224,870
Closed -$1.95K
HOOK
48
DELISTED
HOOKIPA Pharma
HOOK
– –
-12,966
Closed -$1.44K
KALV
49
DELISTED
KalVista Pharmaceuticals
KALV
– –
-67,270
Closed -$1.28K
SPRY icon
50
ARS Pharmaceuticals
SPRY
$612M
– –
-25,000
Closed -$1.16K
1
2
3

Similar funds

MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
WHCM
Wolf Hill Capital Management Greenwich, Connecticut $1.03B AUM 80.44% 1-Year Est. Return
JSC
J. Stern & Co London, United Kingdom $1.03B AUM 20.71% 1-Year Est. Return
IAS
IMA Advisory Services Denver, Colorado $1.02B AUM 18.66% 1-Year Est. Return
CM
Condire Management Dallas, Texas $1.03B AUM 162.78% 1-Year Est. Return
CFFNO
Common Fund For Nonprofit Organizations Wilton, Connecticut $1.03B AUM 22.44% 1-Year Est. Return
MSA
Mason Street Advisors Milwaukee, Wisconsin $1.02B AUM 8.35% 1-Year Est. Return
TBA
Tower Bridge Advisors Conshohocken, Pennsylvania $1.04B AUM 23.66% 1-Year Est. Return

Samsara BioCapital's Q1 2021 Portfolio in Review

As of Q1 2021, Samsara BioCapital held 52 positions worth $542M, up 54,424% from $994K the previous quarter. Its ten largest holdings account for 65% of the portfolio.

Samsara BioCapital deployed $153M of net new capital in Q1 2021, opening 9 new positions and adding to 5 existing holdings. Its largest new stake was Instil Bio: 77,701 shares worth $39M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 48% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was SpringWorks Therapeutics, an estimated $7.26M trimmed.

  • Samsara BioCapital's largest Q1 2021 buy was Instil Bio: 77,701 shares worth $39M.
  • Samsara BioCapital added most to Intercept Pharmaceuticals, Inc. in Q1 2021, an estimated $6.61M increase.
  • Samsara BioCapital's biggest Q1 2021 reduction was SpringWorks Therapeutics, cutting an estimated $7.26M.
  • Samsara BioCapital fully exited Cogent Biosciences in Q1 2021, selling an estimated $6.61K.
  • Samsara BioCapital's ten largest holdings make up 65% of its $542M portfolio in Q1 2021.
  • Samsara BioCapital opened 9 new positions and closed 8 in Q1 2021.
  • Samsara BioCapital's portfolio value rose 54,424% quarter-over-quarter to $542M.

Based on Samsara BioCapital's 13F filing for Q1 2021, filed 18 May 2021.